Kidney Biopsy in Chronic Glomerulonephritis: Diagnostic Standards

Diagnostic Criteria

• Kidney biopsy is the definitive (gold‑standard) test for identifying the specific glomerular injury pattern, underlying etiology, and degree of chronic damage in chronic glomerulonephritis, as endorsed by the American Society of Nephrology. 1

Laboratory Evaluation

Urinalysis

• Demonstration of glomerular hematuria (dysmorphic red blood cells) and/or pyuria without infection is required for the work‑up of suspected chronic glomerulonephritis. 2
• Detection of proteinuria on dipstick is a mandatory component of the initial evaluation. 2

Serologic Testing

• Antineutrophil cytoplasmic antibodies (ANCA; MPO and PR3) should be measured to assess for ANCA‑associated vasculitis. 2
• Antinuclear antibody (ANA) and anti‑double‑stranded DNA testing are indicated to screen for lupus nephritis. 2
• Anti‑GBM antibodies are required to exclude anti‑GBM disease. 2
• Complement C3 and C4 levels are typically reduced in immune‑complex–mediated disease and C3 glomerulopathy. 2
• Serum and urine immunofixation with free light‑chain analysis must be performed when monoclonal immunoglobulin–associated kidney disease is suspected. 3

Indications for Kidney Biopsy

• Perform biopsy when clinical presentation and serologic results suggest glomerulonephritis that requires a specific histologic diagnosis (American Society of Nephrology). 1
• In cases of suspected rapidly progressive glomerulonephritis, biopsy is indicated, but immunosuppressive therapy should not be delayed if ANCA, anti‑GBM, or lupus nephritis is highly suspected. 2
• Biopsy is necessary to differentiate primary from secondary causes of glomerular injury. 1
• Assessment of disease activity versus chronicity to guide treatment decisions requires biopsy. 2

Biopsy Technique and Core Components

• Light microscopy must be performed to identify the glomerular injury pattern (e.g., membranoproliferative, crescentic, sclerosing). (American Society of Nephrology) 1
• Immunofluorescence is essential for detecting immune‑complex deposition patterns (IgA, IgG, IgM, C3, C1q) and complement‑dominant patterns such as C3 glomerulopathy. (American Society of Nephrology) 1
• Immunofluorescence light‑chain restriction (kappa vs. lambda) should be evaluated when monoclonal immunoglobulin disease is suspected. 3
• Electron microscopy is required to localize immune deposits (subepithelial, subendothelial, mesangial, intramembranous). (American Society of Nephrology) 1
• Special stains, including Congo red, must be used to exclude amyloidosis. 3

Quantification of Chronic Damage

• Report the percentage of globally sclerotic glomeruli. (American Society of Nephrology) 1
• Quantify tubular atrophy and interstitial fibrosis (IFTA) as a percentage: mild < 25 %, moderate 25‑50 %, severe > 50 %. (American Society of Nephrology) 1
• Grade vascular changes (arteriosclerosis, arteriolosclerosis) as mild, moderate, or severe. (American Society of Nephrology) 1
• Calculate a chronicity index score to inform prognosis and therapeutic decisions. 4

Imaging

• Renal ultrasound showing increased cortical echogenicity suggests chronic glomerular disease. 5
• Normal or enlarged kidneys on ultrasound are typical of acute presentations or early chronic disease. 5
• Advanced imaging (CT, MRI) is not routinely required for diagnosis unless structural complications are being evaluated. 5

Common Diagnostic Pitfalls

• Delayed biopsy in rapidly progressive disease: Initiate immunosuppression promptly when ANCA‑associated vasculitis, anti‑GBM disease, or lupus nephritis is strongly suspected, and obtain biopsy as soon as feasible. 2
• Inadequate biopsy tissue: Ensure sufficient glomeruli are obtained; the Mayo Clinic/Renal Pathology Society recommends adequate sampling for accurate diagnosis. (American Society of Nephrology) 1
• Missing monoclonal immunoglobulin disease: Perform serum/urine immunofixation with free light chains whenever a membranoproliferative pattern is identified, even if routine immunofluorescence is negative. 3

Special Situations

• HCV‑Associated Glomerulonephritis: Renal biopsy is mandatory in hepatitis C patients with urinary abnormalities or unexplained renal impairment; diffuse membranoproliferative glomerulonephritis occurs in ~80 % of HCV‑related cases. 6

Key Renal Conditions: Diagnosis and Management

Introduction to Membranoproliferative Glomerulonephritis (MPGN)

• MPGN is no longer considered a single disease entity but rather a pattern of glomerular injury with multiple distinct etiologies that must be differentiated by immunofluorescence patterns 7
• The classification is based on three immunofluorescence patterns: immune complex-mediated, complement-dominant, and immunofluorescence-negative 8, 9

Diagnostic Workup for MPGN

• For C3 glomerulopathy, genetic screening for mutations in C3, complement factors H/I/B, CD46, and CFHR 1-5 is recommended in children 8, 9
• In adults, testing for acquired autoantibodies including C3 nephritic factor (C3Nef) and anti-factor H antibody is recommended 8, 9

Treatment Approach for MPGN

• For idiopathic MPGN with nephrotic syndrome and progressive renal decline, treatment with oral cyclophosphamide or MMF plus low-dose alternate-day or daily corticosteroids for less than 6 months is recommended 8, 9
• Patients with advanced CKD, severe tubulointerstitial fibrosis, small kidneys, or chronic inactive disease should not be treated with immunosuppression 8

Nephrotic Syndrome

• When nephrotic syndrome occurs with detectable serum/urine monoclonal immunoglobulin, the MIg type (kappa vs lambda) should be specified in the diagnosis 10, 11

Nephritic Syndrome

• Nephritic syndrome is characterized by hematuria, proteinuria, hypertension, and in some cases acute kidney injury and fluid retention, all characteristic of acute glomerulonephritis 12
• Rapidly progressive glomerulonephritis (RPGN) with rapid decline in kidney function over days to weeks constitutes a medical emergency and must not be missed 12, 13

Diagnostic Workup for RPGN

• Essential serologies include ANCA, ANA, anti-GBM antibodies, and complement levels 13
• Kidney biopsy is crucial to confirm diagnosis and assess disease activity versus chronicity 13

Treatment of RPGN

• Early diagnosis and prompt initiation of immunosuppressive therapy are critical for favorable outcomes 13
• For ANCA-associated vasculitis, induction with cyclophosphamide or rituximab plus glucocorticoids is recommended 13

Tubulointerstitial Disease

• When reporting renal biopsies, additional findings must include the extent of tubular atrophy and interstitial fibrosis (quantified as percentage) 10, 11

Urinary Tract Infection (Acute Pyelonephritis)

• Diabetic patients are particularly vulnerable to complications including renal abscesses and emphysematous pyelonephritis 14
• Imaging is NOT indicated for initial evaluation of uncomplicated acute pyelonephritis 14

HCV-Associated Cryoglobulinemic Nephritis

• Three main glomerular patterns from cryoglobulin deposition are seen in HCV-associated cryoglobulinemic nephritis: diffuse membranoproliferative glomerulonephritis, mesangial proliferative pattern, and membranous pattern 15
• Renal biopsy is mandatory in any HCV patient with urinary abnormalities and/or unexplained renal impairment 15

Acute Renal Failure

• Creatinine >3 mg/dL severely limits drug efficacy and enhances toxicity, requiring urgent intervention 12
• Creatinine >5 mg/dL may require hemofiltration or dialysis 12